



**Yash M. Patel**

Age : 21 Years

Sex : Male

PID : 555



**Sample Collected At:**

125, Shivam Bungalow, S G Road,  
Mumbai

Ref. By: **Dr. Hiren Shah**



Registered on: 02:31 PM 02 Dec, 2X


Collected on: 03:11 PM 02 Dec, 2X

Reported on: 04:35 PM 02 Dec, 2X

## HER2 (ERBB2) Amplification Fluorescence in-situ Hybridization (FISH)

|                            |  |
|----------------------------|--|
| <b>Specimen</b>            | : Formalin fixed paraffin embedded tissue block  |
| <b>Block no.</b>           | : 3446A/19 (10% Tumor)   |
| <b>Fixation Time</b>       | : 20:00  |
| <b>Clinical Indication</b> | : To rule out Her-2/neu gene amplification   |
| <b>Result</b>              | : Her2 gene:CEP17 ratio: <b>5.53</b>   |
| <b>Interpretation</b>      | : The tumor cells are <b>Positive</b> for HER-2 gene amplification as per ASCO / CAP 2018 guidelines in this specimen. |

|                             |       |
|-----------------------------|-------|
| Cells Counted               | 30    |
| Total Her2 signals          | 415   |
| Total CEP17 signals         | 7S    |
| Her2 signals mean per cell  | 13.83 |
| CEP17 signals mean per cell | 2.5   |
| Her2/neu:CEP17 ratio        | 5.53  |



### Comment :

Her2 (ERBB2) is an oncogene on the long arm of chromosome 17 that is amplified in approximately 15-20% of Breast cancers. Overexpression of Her2 has been shown to be associated with shorter disease free survival and poorer overall survival in breast cancer. Patients with Her2 gene amplification are candidates for treatment with the drugs that target human epidermal growth factor receptor 2 (Her2) protein & its downstream pathways e.g. Trastuzumab, Pertuzumab.

### Uses :

- A predictive marker for patients with both node-positive or node-negative primary & metastatic breast cancer
- Confirming the presence of Her2 amplification in cases with 2+ or 3+ Her2 overexpression by IHC
- For confirmation of aberrant patterns of Her2 expression seen by IHC like in cases of Micropapillary carcinoma

**\*Note:** This is a Laboratory developed test (LDT), developed at Drlogy PathLabs and has not been cleared or approved for specific uses by FDA

Thanks for Reference

\*\*\*\*End of Report\*\*\*\*

**Medical Lab Technician**  
(DMLT, BMLT)

**Dr. Payal Shah**  
(MD, Pathologist)

**Dr. Vimal Shah**  
(MD, Pathologist)

